A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis
Public ClinicalTrials.gov record NCT06087406. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Imvotamab in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Failed Prior Therapies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the safety and tolerability of imvotamab in patients with moderate to severe rheumatoid arthritis who have failed prior therapies. Participants will be given imvotamab or placebo through a vein (i.e., intravenously). A placebo is a look-alike substance that contains no active drug
Study identification
- NCT ID
- NCT06087406
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 33 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 14, 2023
- Primary completion
- Feb 9, 2025
- Completion
- Feb 9, 2025
- Last update posted
- Feb 17, 2025
2023 – 2025
United States locations
- U.S. sites
- 10
- U.S. states
- 6
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Arthritis & Rheumatology Research, PLLC | Flagstaff | Arizona | 860001 | — |
| Arizona Arthritis & Rheumatology Research, PLLC | Glendale | Arizona | 85306 | — |
| Triwest Research Associates | San Diego | California | 92108 | — |
| East Bay Rheumatology Medical Group | San Leandro | California | 94578 | — |
| University of Colorado Hopsital - Anschutz Medical Campus | Aurora | Colorado | 80045 | — |
| Arthritis and Rheumatic Disease Specialties | Aventura | Florida | 33180 | — |
| Omega Research MetroWest | Orlando | Florida | 32855 | — |
| Integral Rheumatology & Immunology Specialists | Plantation | Florida | 33324 | — |
| Accelacare - Salisbury | Salisbury | North Carolina | 28144 | — |
| Southwest Rheumatology Research | Mesquite | Texas | 75150 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06087406, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 17, 2025 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06087406 live on ClinicalTrials.gov.